Receptor-tethered orthogonal IL-2 enhances regulatory T cell therapy
Journal of Experimental Medicine · 07.09.2026 · 223 (9)
DOI: 10.1084/jem.20251480 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 12.08.2026. Verfasst von Alyssa C Indart und 11 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Center, University of California, San Francisco , San Francisco, CA, USA. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Interleukin-2, Receptors, Interleukin-2, Diabetes Mellitus, Type 1. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIAID NIH HHS, University of California, San Francisco.
Abstract (Originalsprache)
Regulatory T cell (Treg) therapy is an emerging platform for controlling immune overactivation. Persistence of infused Tregs is limited by insufficient IL-2, which is essential for Treg survival and function. IL-2 activates many immune cells, imposing a challenge for the selective provision of IL-2 to infused Tregs. In this study, we found that infusions of orthogonal (ortho) IL-2 failed to enhance Tregs expressing a corresponding orthoIL-2 receptor (IL-2R) in a mouse model of autoimmune diabetes. Engineering Tregs with an orthoIL-2 tethered to its receptor achieved selective autocrine signaling; increased CD25, CTLA-4, and Foxp3 expression; supported Treg persistence without exogenous IL-2 in vivo; and improved the efficacy of Treg prevention of autoimmune diabetes. Inserting the tethered orthoIL-2 construct into the Foxp3 locus enabled Treg-specific self-reinforced expression through the activation of the Foxp3 locus by increased IL-2 signaling. Together, these results illustrate a safe and effective cell-engineering solution for overcoming Tregs’ dependency on exogenous IL-2, thereby achieving superior therapeutic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Diabetes Center, University of California, San Francisco , San Francisco, CA, USA.
- Gladstone-UCSF Institute of Genomic Immunology , San Francisco, CA, USA.
- Department of Otolaryngology-Head and Neck Surgery, Stanford University, Stanford, CA, USA.
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA, USA.
- Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
ORCID-Profile: Alyssa C Indart, Huiyun Lyu, Vinh Q Nguyen, Wendy Rosenthal, Jatin R Palvai, Sophie S Jang, Yue Chen, Kevin Jude, Leon Su, K Christopher Garcia, Jeffrey A Bluestone, Qizhi Tang
Förderung
- NIDDK NIH HHS
- NIAID NIH HHS
- University of California, San Francisco
- NIH HHS
- Klein-Kraft 2022-2023 Diabetes Research Fellowships
- Sean Parker Autoimmune Laboratory Fund
- Breakthrough T1D
- Ludwig Institute
Zitieren
APA
Indart, A. C., Lyu, H., Nguyen, V. Q., Rosenthal, W., Palvai, J. R., Jang, S. S., Chen, Y., Jude, K., Su, L., Garcia, K. C., Bluestone, J. A., & Tang, Q. (2026). Receptor-tethered orthogonal IL-2 enhances regulatory T cell therapy. Journal of Experimental Medicine, 223(9). https://doi.org/10.1084/jem.20251480
Vancouver
Indart AC, Lyu H, Nguyen VQ, Rosenthal W, Palvai JR, Jang SS, et al. Receptor-tethered orthogonal IL-2 enhances regulatory T cell therapy. Journal of Experimental Medicine. 2026;223(9). doi:10.1084/jem.20251480
BibTeX
@article{Indart2026,
author = {Indart, Alyssa C and Lyu, Huiyun and Nguyen, Vinh Q and Rosenthal, Wendy and Palvai, Jatin R and Jang, Sophie S and Chen, Yue and Jude, Kevin and Su, Leon and Garcia, K Christopher and Bluestone, Jeffrey A and Tang, Qizhi},
title = {Receptor-tethered orthogonal IL-2 enhances regulatory T cell therapy},
journal = {Journal of Experimental Medicine},
year = {2026},
volume = {223},
number = {9},
doi = {10.1084/jem.20251480}
}
EUVIMED